Heparins Attenuate Cancer Metastasis: Are Selectins the Link?

REFERENCES

• Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106(13)4027–4033
   PubMed Web of Science ®Google Scholar
• Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31(1)104–110
   PubMed Web of Science ®Google Scholar
• Lip G. Y., Chin B. S., Blann A. D. Cancer and the prothrombotic state. Lancet Oncol 2002; 3(1)27–34
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102(6)V215–V224
   PubMed Web of Science ®Google Scholar
• Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110(6)1723–1729
   PubMed Web of Science ®Google Scholar
• Palumbo J. S., Talmage K. E., Massari J. V., La Jeunesse C. M., Flick M. J., et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007; 110(1)133–141
   PubMed Web of Science ®Google Scholar
• Ruf W., Mueller B. M. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32(Suppl. 1)61–68
   PubMedGoogle Scholar
• Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., Sottile A., Naldini L., Comoglio P. M. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434(7031)396–400
   PubMed Web of Science ®Google Scholar
• Denko N. C., Giaccia A. J. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001; 61(3)795–798
   PubMed Web of Science ®Google Scholar
• Wahrenbrock M., Borsig L., Le D., Varki N., Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112(6)853–862
   PubMed Web of Science ®Google Scholar
• Ornstein D. L., Zacharski L. R. The use of heparin for treating human malignancies. Haemostasis 1999; 29(Suppl. S1)48–60
   PubMedGoogle Scholar
• Kakkar A. K., Hedges A. R., Williamson R. C.N., Kakkar V. V. Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol 1995; 6: 885–888
   PubMed Web of Science ®Google Scholar
• Kuderer N. M., Khorana A. A., Lyman G. H., Francis C. W. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110(5)1149–1161
   PubMed Web of Science ®Google Scholar
• Tagalakis V., Blostein M., Robinson-Cohen C., Kahn S. R. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007; 33(4)358–368
   PubMed Web of Science ®Google Scholar
• Lever R., Page C. P. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002; 1(2)140–148
   PubMed Web of Science ®Google Scholar
• Zacharski L. R., Ornstein D. L., Mamourian A. C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000; 26(Suppl. 1)69–77
   PubMedGoogle Scholar
• Smorenburg S. M., Van Noorden C. J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53(1)93–105
   PubMed Web of Science ®Google Scholar
• Varki N. M., Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002; 28(1)53–66
   PubMed Web of Science ®Google Scholar
• Borsig L., Stevenson J. L., Varki A. Heparin in cancer: role of selectin interactions. In Cancer-Associated Thrombosis, A. A. Khorana, C. W. Francis. Informa Healthcare, New York 2007; 97–113
   Google Scholar
• Lebeau B., Chastang C., Brechot J. M., Capron F., Dautzenberg B., Delaisements C., Mornet M., Brun J., Hurdebourcq J. P., Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994; 74(1)38–45
   Google Scholar
• Altinbas M., Coskun H. S., Er O., Ozkan M., Eser B., Unal A., Cetin M., Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2(8)1266–1271
   PubMed Web of Science ®Google Scholar
• Sideras K., Schaefer P. L., Okuno S. H., Sloan J. A., Kutteh L., Fitch T. R., Dakhil S. R., Levitt R., Alberts S. R., Morton R. F., Rowland K. M., Novotny P. J., Loprinzi C. L. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81(6)758–767
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., Lemoine N. R., Low V., Patel H. K., Rustin G., Thomas M., Quigley M., Williamson R. C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22(10)1944–1948
   PubMed Web of Science ®Google Scholar
• Klerk C. P., Smorenburg S. M., Otten H. M., Lensing A. W., Prins M. H., Piovella F., Prandoni P., Bos M. M., Richel D. J., van Tienhoven G., Buller H. R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23(10)2130–2135
   PubMed Web of Science ®Google Scholar
• Lazo-Langner A., Goss G. D., Spaans J. N., Rodger M. A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5(4)729–737
   Web of Science ®Google Scholar
• Lee A. Y., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., Rickles F. R., Julian J. A., Haley S., Kovacs M. J., Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2)146–153
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Rickles F. R., Julian J. A., Gent M., Baker R. I., Bowden C., Kakkar A. K., Prins M., Levine M. N. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23(10)2123–2129
   PubMed Web of Science ®Google Scholar
• Lee A. E., Rogers L. A., Longcroft J. M., Jeffery R. E. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin Exp Metastasis 1990; 8(2)165–171
   PubMed Web of Science ®Google Scholar
• Kragh M., Binderup L., Vig Hjarnaa P. J., Bramm E., Johansen K. B., Frimundt Petersen C. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep 2005; 14(1)99–104
   PubMed Web of Science ®Google Scholar
• Vlodavsky I., Mohsen M., Lider O., Svahn C. M., Ekre H. P., Vigoda M., Ishai-Michaeli R., Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994; 14(1–6)290–302
   PubMedGoogle Scholar
• Borsig L., Wong R., Feramisco J., Nadeau D. R., Varki N. M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98(6)3352–3357
   PubMed Web of Science ®Google Scholar
• Borsig L., Wong R., Hynes R. O., Varki N. M., Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99(4)2193–2198
   PubMed Web of Science ®Google Scholar
• Ludwig R. J., Boehme B., Podda M., Henschler R., Jager E., Tandi C., Boehncke W. H., Zollner T. M., Kaufmann R., Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64(8)2743–2750
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y., Nakanishi H., Kusano Y., Munesue S., Oguri K., Tatematsu M., Yamashina I., Okayama M. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004; 207(2)165–174
   PubMed Web of Science ®Google Scholar
• Stevenson J. L., Choi S. H., Varki A. Differential metastasis inhibition by clinically relevant levels of heparins–correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11(19)7003–7011
   PubMed Web of Science ®Google Scholar
• Ludwig R. J., Alban S., Bistrian R., Boehncke W. H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95(3)535–540
   PubMed Web of Science ®Google Scholar
• Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999; 85(2)257–272
   PubMed Web of Science ®Google Scholar
• Folkman J., Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355–364
   PubMedGoogle Scholar
• Harvey J. R., Mellor P., Eldaly H., Lennard T. W., Kirby J. A., Ali S. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?. Clin Cancer Res 2007; 13(5)1562–1570
   PubMed Web of Science ®Google Scholar
• Mellor P., Harvey J. R., Murphy K. J., Pye D., O'Boyle G., Lennard T. W., Kirby J. A., Ali S. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 2007; 97(6)761–768
   PubMed Web of Science ®Google Scholar
• Amirkhosravi A., Mousa S. A., Amaya M., Francis J. L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1(9)1972–1976
   PubMed Web of Science ®Google Scholar
• Fareed J., Hoppensteadt D. A., Bick R. L. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000; 26(Suppl 1)5–21
   PubMedGoogle Scholar
• Zacharski L. R., Ornstein D. L. Heparin and cancer. Thromb Haemost 1998; 80(1)10–23
   PubMed Web of Science ®Google Scholar
• Niers T. M., Klerk C. P., DiNisio M., Van Noorden C. J., Buller H. R., Reitsma P. H., Richel D. J. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61(3)195–207
   PubMed Web of Science ®Google Scholar
• Hostettler N., Naggi A., Torri G., Casu B., Vlodavsky I., Borsig L. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007; 21(13)3562–3572
   PubMed Web of Science ®Google Scholar
• Lapierre F., Holme K., Lam L., Tressler R. J., Storm N., Wee J., Stack R. J., Castellot J., Tyrrell D. J. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996; 6(3)355–366
   PubMed Web of Science ®Google Scholar
• Ono K., Ishihara M., Ishikawa K., Ozeki Y., Deguchi H., Sato M., Hashimoto H., Saito Y., Yura H., Kurita A., Maehara T. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 2002; 86(11)1803–1812
   PubMed Web of Science ®Google Scholar
• Sciumbata T., Caretto P., Pirovano P., Pozzi P., Cremonesi P., Galimberti G., Leoni F., Marcucci F. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996; 16(3)132–143
   PubMedGoogle Scholar
• Hu L., Lee M., Campbell W., Perez-Soler R., Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104(9)2746–2751
   PubMed Web of Science ®Google Scholar
• Im J. H., Fu W., Wang H., Bhatia S. K., Hammer D. A., Kowalska M. A., Muschel R. J. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004; 64(23)8613–8619
   PubMed Web of Science ®Google Scholar
• Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38(12)2018–2039
   PubMed Web of Science ®Google Scholar
• Edovitsky E., Elkin M., Zcharia E., Peretz T., Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004; 96(16)1219–1230
   PubMed Web of Science ®Google Scholar
• Miao H. Q., Elkin M., Aingorn E., Ishai-Michaeli R., Stein C. A., Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999; 83(3)424–431
   PubMed Web of Science ®Google Scholar
• Parish C. R., Freeman C., Brown K. J., Francis D. J., Cowden W. B. Identification of sulfated oligosaccharide based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59(14)3433–3441
   PubMed Web of Science ®Google Scholar
• Honn K. V., Tang D. G., Crissman J. D. Platelets and cancer metastasis: a causal relationship?. Cancer Metastasis Rev 1992; 11: 325–351
   PubMed Web of Science ®Google Scholar
• Karpatkin S., Pearlstein E., Ambrogio C., Coller B. S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81(4)1012–1019
   PubMed Web of Science ®Google Scholar
• Nieswandt B., Hafner M., Echtenacher B., Mannel D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59(6)1295–1300
   PubMed Web of Science ®Google Scholar
• Tanaka N. G., Tohgo A., Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases. Invasion Met 1986; 6(4)209–224
   PubMedGoogle Scholar
• Gasic G. J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984; 3: 99–114
   PubMed Web of Science ®Google Scholar
• Fuster M. M., Brown J. R., Wang L., Esko J. D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 2003; 63(11)2775–2781
   PubMed Web of Science ®Google Scholar
• Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci 2004; 19: 16–21
   PubMedGoogle Scholar
• Garcia J., Callewaert N., Borsig L. P-selectin mediates metastatic progression through binding to sulfatides on carcinoma cells. Glycobiology 2007; 17(2)185–196
   PubMed Web of Science ®Google Scholar
• Coussens L. M., Werb Z. Inflammation and cancer. Nature 2002; 420(6917)860–867
   PubMed Web of Science ®Google Scholar
• Pollard J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1)71–78
   PubMed Web of Science ®Google Scholar
• Laubli H., Stevenson J. L., Varki A., Varki N. M., Borsig L. L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 2006; 66(3)1536–1542
   PubMed Web of Science ®Google Scholar
• Kansas G. S. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259–3287
   PubMed Web of Science ®Google Scholar
• Lowe J. B. Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Kidney Int 1997; 51: 1418–1426
   PubMed Web of Science ®Google Scholar
• McEver R. P. Selectin-carbohydrate interactions during inflammation and metastasis. 1997; 14(5)585–591
   Google Scholar
• Kim Y. S., Gum J., Brockhausen I., Jr. Mucin glycoproteins in neoplasia. Glycoconj J 1996; 13: 693–707
   PubMed Web of Science ®Google Scholar
• Kim Y. J., Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997; 14(5)569–576
   PubMed Web of Science ®Google Scholar
• Yang J. M., Byrd J. C., Siddiki B. B., Chung Y. S., Okuno M., Sowa M., Kim Y. S., Matta K. L., Brockhausen I. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology 1994; 4: 873–884
   PubMed Web of Science ®Google Scholar
• Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., Kabuto T., Iwanaga T., Matsushita Y., Irimura T. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632–3637
   PubMed Web of Science ®Google Scholar
• Tatsumi M., Watanabe A., Sawada H., Yamada Y., Shino Y., Nakano H. Immunohistochemical expression of the sialyl Lewis x antigen on gastric cancer cells correlates with the presence of liver metastasis. Clin Exp Metastasis 1998; 16(8)743–750
   PubMed Web of Science ®Google Scholar
• Ogawa J. I., Inoue H., Koide S. alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. Cancer 1997; 79(9)1678–1685
   PubMed Web of Science ®Google Scholar
• Ogawa J., Tsurumi T., Yamada S., Koide S., Shohtsu A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 1994; 73(4)1177–1183
   Google Scholar
• Jorgensen T., Berner A., Kaalhus O., Tveter K. J., Danielsen H. E., Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55(9)1817–1819
   PubMed Web of Science ®Google Scholar
• Idikio H. A. Sialyl-Lewis-X, Gleason grade and stage in non-metastatic human prostate cancer. Glycoconj J 1997; 14(7)875–877
   PubMed Web of Science ®Google Scholar
• Renkonen J., Paavonen T., Renkonen R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer 1997; 74(3)296–300
   PubMed Web of Science ®Google Scholar
• Yamaguchi A., Ding K., Maehara M., Goi T., Nakagawara G. Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer. Oncology 1998; 55(4)357–362
   PubMed Web of Science ®Google Scholar
• Bevilacqua M. P., Nelson R. M. Endothelial-leukocyte adhesion molecules in inflammation and metastasis. Thromb Haemost 1993; 70(1)152–154
   PubMed Web of Science ®Google Scholar
• Slattery M. J., Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer 2003; 106(5)713–722
   PubMed Web of Science ®Google Scholar
• Wu Q. D., Wang J. H., Condron C., Bouchier-Hayes D., Redmond H. P. Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 2001; 280(4)C814–C822
   PubMed Web of Science ®Google Scholar
• Liang S., Sharma A., Peng H. H., Robertson G., Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 2007; 67(12)5814–5820
   PubMed Web of Science ®Google Scholar
• Koenig A., Norgard-Sumnicht K., Linhardt R., Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877–889
   Google Scholar
• Nelson R. M., Cecconi O., Roberts W. G., Aruffo A., Linhardt R. J., Bevilacqua M. P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253–3258
   PubMed Web of Science ®Google Scholar
• Stevenson J. L., Varki A., Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007; 120(Suppl. 2)S107–S111
   PubMedGoogle Scholar
• Fidler I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50: 6130–6138
   PubMed Web of Science ®Google Scholar
• Chambers A. F., Groom A. C., MacDonald I. C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2(8)563–572
   PubMed Web of Science ®Google Scholar
• Cristofanilli M., Budd G. T., Ellis M. J., Stopeck A., Matera J., Miller M. C., Reuben J. M., Doyle G. V., Allard W. J., Terstappen L. W., Hayes D. F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351(8)781–791
   PubMed Web of Science ®Google Scholar
• Cristofanilli M., Hayes D. F., Budd G. T., Ellis M. J., Stopeck A., Reuben J. M., Doyle G. V., Matera J., Allard W. J., Miller M. C., Fritsche H. A., Hortobagyi G. N., Terstappen L. W. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23(7)1420–1430
   PubMed Web of Science ®Google Scholar